



## CASE STUDY II



### A multi-year analysis of the value of a Comprehensive Medication Review program

Calculating the value of a single comprehensive medication review (CMR) will vary by application, but recent data from **Community Health Group** gives evidence of year-over-year increase of financial savings and improved health outcomes.

#### 2020 Member Inclusion Criteria

Similar to criteria used by most Medicare plans, the CHG members in this study:

- Have 3 or more of selected chronic diseases
- Take at least 8 covered Part D medications
- Incur one-fourth of the annual costs threshold (\$4,255) for covered Part D drugs in previous three months or \$1,063 quarterly

#### 2019 & 2020 Study Population

787 total patients received a CMR in both 2019 and 2020

- Avg Age: 73.3
- Gender: 58% female
- Top 3 primary languages: 36% Spanish, 32% English, 26% Vietnamese

Overall in 2019 and 2020 CHG members who receiver a CMR:



spent less time in the hospital



recorded improved health outcomes



saw a reduced medical spend

## Stronger Results Year Over Year

From 2019 – 2020 healthcare spending nationwide grew by an astounding 9.7%\*. Even in the wake of increased healthcare spend, the benefit of a CMR rang true for CHG. In CY2020, **members who received a CMR had a 16.7% lower average amount paid per member for total cost of care** as compared to members who did not receive a CMR. That's up from 2019's 5% lower average amount per member for total cost of care.

\* <https://www.cms.gov/files/document/highlights.pdf>

Year 1:  
Members receiving  
a CMR averaged  
**5%**


lower total cost of care  
compared to members who did not

Year 2:  
Members receiving  
a CMR averaged  
**16.7%**

lower total cost of care  
compared to members who did not



### 2019 vs 2020 medical expense reduction in patients receiving CMRs



*While not all patients in the study received a CMR in both 2019 and 2020, the overall financial impact recorded by CHG for the CMR group showed additional savings year two, often even greater than the year prior.*

#### Study Limitations

The COVID-19 pandemic was the primary contributing factor in the national increase of healthcare spending. To fully understand the longitudinal impacts of the analysis, a third year study should be conducted to determine long term value of the CMR.

- Control and treatment groups were not equal in size; more patients got the CMR than did not.
- The study involved a small population in a geographically focused area of the United States (California)



## We'd love to discuss more.

833.723.1743 | [info@getoutcomes.com](mailto:info@getoutcomes.com) | [getoutcomes.com](https://getoutcomes.com)